|Cell Line Name：||TFG-NTRK1/BaF3|
|Stability:||16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)|
|Application:||Anti-proliferation assay and PD assay|
|Freeze Medium:||90% FBS+10% DMSO|
|Complete Culture Medium:||RPMI-1640+10% FBS+1 ug/ml puromycin|
|NTRK1 rearrangements involve the kinase domain of the NTRK1 gene which includes 17 exons located on chromosome 1q21-22 (Alberti et al. 2003). The frequency of NTRK1 fusions in patients with adenocarcinoma histology is 3.3% of cases (3 out of 91 patients; Vaishnavi et al. 2013).
a In preclinical studies, cell lines expressing MPRIP-NTRK1 or CD74-NTRK1 were inhibited by ARRY-470, a TRKA/B/C inhibitor (Vaishnavi et al. 2013).
b In preclinical studies, cell lines expressing MPRIP-NTRK1 or CD74-NTRK1 were inhibited by lestaurtinib, a FLT3/TRKA inhibitor (Vaishnavi et al. 2013).
c A patient with non-small cell lung cancer harboring an MPRIP-NTRK1 fusion mutation was treated with crizotinib, which has activity against TRKA in addition to ALK, MET and ROS1 (Vaishnavi et al. 2013). The patient demonstrated a small radiographic decrease in tumor size but experienced disease progression after three months (Vaishnavi et al. 2013)
|III. Representative Data|
1. WB of TFG-NTRK1/BaF3 expression
2. Anti-proliferation assay
Figure 2. Anti-proliferation assay of two reference compounds on the TFG-NTRK1/BaF3 Stable Cell Line